INTRODUCTION
============

Neuronal apoptosis is widespread during the development of the nervous system and in chronic neurodegenerative diseases such as Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease ([@B2]; [@B20]; [@B31]; [@B7]). RGC (retinal ganglion cell) death, and the degeneration of their axons in the optic nerve, is the principal characteristic of blinding optic neuropathies such as glaucoma ([@B40]). Previously we, and others, have documented an essential role for *Bax* expression and the intrinsic apoptotic pathway in the process of RGC death in development, after acute nerve trauma and in a mouse model of chronic glaucoma ([@B17]; [@B38]; [@B18]; [@B27]; [@B29]).

The intrinsic apoptotic pathway involves mitochondrial dysfunction and is regulated by members of the *Bcl2* gene family ([@B1]). In this pathway, the molecular events leading to cell death cause the release of cytochrome *c* through permeabilization of the mitochondria by the pro-apoptotic proteins BAX and BAK. The release of cytochrome *c* subsequently activates the caspase cascade via its association with pro-caspase 9 and the apoptosis protease activating factor-1 ([@B8]; [@B1]). In most cell types, the functions of BAX and BAK are similar, and therefore redundant with the exception of some cancer cells ([@B55]) and many neurons ([@B22]; [@B9]; [@B53]), in which BAX is the central mediator of apoptosis. In neurons, the exclusive role for BAX may result from alternative splicing of *Bak* transcripts, which result in the translation of a truncated form of BAK (N-BAK) containing only the BH3 domain ([@B52]).

Mouse genetic studies manipulating the *Bax* gene showed that *Bax* knockout mice on a mixed 129/Sv and C57BL/6 background (129B6) ([@B22]) exhibited reduced developmental neuronal death throughout the central and peripheral nervous system compared with wild-type mice ([@B9]; [@B38]; [@B53]). Similarly, *Bax* deficiency prevented sympathetic neuron death in the absence of nerve growth factor in culture. *In vivo*, *Bax* deficiency promoted motor neuron survival following both facial and sciatic nerve axotomy, and RGC survival following ONC (optic nerve crush) ([@B9]; [@B27]; [@B50]). In *Bax*^+/−^ mice, however, developmental apoptosis of sympathetic and facial motor neurons, and RGCs, was comparable with wild-type mice. In addition, motor neuron death after facial nerve axotomy was comparable between *Bax*^+/−^ and wild-type mice ([@B9]; [@B38]). Collectively, these studies suggested that expression from a single copy of *Bax* was sufficient to execute apoptosis in mice with the 129B6 mixed genetic background.

Similar to 129B6 mice, complete *Bax* deficiency in the DBA/2J mouse line prevented RGC soma death during glaucoma and after ONC ([@B29]). DBA/2J mice develop chronic secondary glaucoma at 10--12 months of age characterized by elevated intraocular pressure, optic nerve degeneration, and the progressive loss of RGCs ([@B6]; [@B30]; [@B47]). In contrast with 129B6 mice, however, DBA/2J mice heterozygous for the *Bax* allele did not exhibit significant RGC death shortly after ONC and in glaucoma, whereas wild-type animals did ([@B29]). Thus reduced *Bax* expression, at least on some genetic backgrounds, was able to significantly affect RGC soma susceptibility to optic nerve damage.

In the present study, we examine the underlying cause for the differential cell death phenotype between 129B6 and DBA/2J mice heterozygous for the mutant *Bax* allele. This difference is associated with higher levels of latent *Bax* mRNA and protein in the neurons of 129B6 mice. Promoter analysis also identified a single nucleotide polymorphism in the *Bax* promoter of each strain, which can significantly alter the level of expression of this gene, and affect the binding affinity of nuclear proteins.

MATERIALS AND METHODS
=====================

Animals
-------

Mice used in the present study were maintained and handled in accordance with the guidelines established by the Association for Research in Vision and Ophthalmology Statement on Animals in Research and overseen by the Animal Care and Use Committee at the University of Wisconsin. A colony of mice deficient for *Bax* ([@B22]) was established from breeders obtained from the late Dr Stanley Korsmeyer and maintained as an inbred population. In this line, the null allele was initially generated in 129/Sv-derived embryonic stem cells, which were introduced into C57BL/6 embryos. We have designated these mice as 129B6 because of their mixed genetic background. DBA/2J mice congenic for the *Bax* null allele ([@B29]) were generously provided by Dr Simon John (Bar Harbor, ME, U.S.A.). FVB mice were a gift from Dr Paul Lambert (School of Medicine and Public Health, University of Wisconsin, Madison, WI, U.S.A.).

ONC and ganglion cell counting
------------------------------

ONC surgery was performed as described previously ([@B26]). ONC causes synchronous RGC death in the ganglion cell layer, which accounts for 50--60% of the neurons in this layer. Only the left eye of each mouse underwent surgery, leaving the other eye as a control. The loss of cells in the retinal ganglion cell layer was quantified as described previously ([@B28]).

Cell culture
------------

All cells were maintained in a humidified incubator at 37°C with 5% CO~2~ and media replaced every 2--3 days. NIH 3T3 cells, an immortalized murine fibroblast cell line, were a gift from Dr Donna Peters (Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, U.S.A.). The cells were grown in DMEM (Dulbecco's modified Eagle's medium) containing 4.5 g/l glucose with [l]{.smallcaps}-glutamine (Cambrex) supplemented with 10% FBS (fetal bovine serum) (Atlanta Biologicals) and with 1% penicillin/streptomycin (Cambrex). NIH 3T3 cells were passaged at 70--80% confluency. RGC-5 cells ([@B24]), an immortalized rat retinal ganglion cell line, were a gift from Dr Neeraj Agarwal (Vision Research Program, National Eye Institute, Rockville, MD, U.S.A.). RGC-5 cells were cultured in DMEM containing 10% FBS, 1 g/l glucose and 1% penicillin/streptomycin. Primary lung fibroblasts from 2-month-old FVB mice (p53^+/+^ and p53^−/−^ genotypes) and 3-month-old DBA/2J*^Bax^*^+/+^ mice were isolated as described previously ([@B23]). Briefly, lungs from each mouse were aseptically dissected and minced into ∼1 mm pieces. The tissue was washed three times with PBS containing 2% penicillin/streptomycin and treated with 0.25% trypsin for 10 min. The tissue was washed again with PBS and treated for 5 h with 169 units/mg of 0.3% collagenase type I (Worthington). The dissociated cells and tissue were split into three 10-cm-diameter plates in 4.5 g/l glucose-containing DMEM with [l]{.smallcaps}-glutamine, 15% FBS, and 1% penicillin/streptomycin. The resulting fibroblasts were allowed to become confluent before being passed. Cells were cryogenically frozen after 10 days in culture until use. All experiments using primary fibroblasts were performed at the third passage.

Clones and plasmids
-------------------

A 3091 bp genomic fragment containing the DBA/2J or 129B6 *Bax* promoter region, including exon 1 and half of intron 1, was PCR-amplified using LA Taq (Takara). The primer sequences used were: 5′-GATTAGGTTGGCTTGTTTGTGG (forward) and 5′-CTAGTAGTGACAAGTAGCATGG (reverse). Nhe1 and Bgl II sites were engineered into the promoter regions by nested PCR to isolate 1370 bp directly upstream of the start codon using the primers 5′-GTGATCTTACGCTAGCTTCCTGCGTTCTGAGG (forward containing Nhe1) and 5′-CGAACTGTCTAGATCTCACTGCCGCTGCCTCTCG (reverse containing BglII). The nucleotide directly upstream of the start codon was considered −1 and the numbering of all other nucleotides is relative to this position. This fragment was directionally cloned into pGL3-Basic (Promega), a Luc (luciferase) expression vector, to create the DBA/2J--Luc and 129B6--Luc reporter constructs. The expression plasmid containing human p53 under the control of the CMV promoter (pC53-SN~3~) was a gift from Dr Mary Ellen Perry (National Cancer Institute, Rockville, MD, U.S.A.) and the plasmid containing 13 p53 response elements ([@B21]) with a Luc reporter (pG~13~-Luc) was a gift from Dr Bert Vogelstein (Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, U.S.A.). All clones were sequenced at the University of Wisconsin Biotechnology Center. The pGL3-Basic plasmid was used as a negative control for Luc experiments, pGL3-Control (Promega) was used as a positive control, and pSV-βgal (βgal, β-galactosidase) (Promega) was used to determine transfection efficiency.

RNA isolation and quantitative PCR
----------------------------------

Total RNA was isolated from whole retina tissue and cultured cells using Tri-reagent (Molecular Research Center, Cincinnati, OH, U.S.A.). First-strand cDNA was synthesized using oligo-dT as a primer, and quantitative PCR was performed using the ABI (Applied Biosystems) 7300 real-time PCR system and ABI SYBR Green PCR Master Mix as described previously ([@B42]). Standard curves were generated for each product using cloned cDNAs for *Bax*,*Bcl-X* and the *S16* ribosomal protein to quantify the abundance of cDNA in each sample. The *Bax* coding region (627 bp fragment) was isolated from DBA/2J and 129B6 retinal cDNA with the following primers: 5′-ACCCGCCGAGAGGCAGCG (forward) and 5′-CACAGTCCCAGGCAGTGGG (reverse) and blunt-end cloned the SmaI site of pBK-CMV (Stratagene). *BclX* was blunt-end cloned into pBK-CMV using the primers 5′-CATCTCACCTACCAGTCA (forward) and 5′-GTCAGAGTGGATGGTCAGT (reverse). A cDNA for *S16* (199 bp fragment) was also blunt-end cloned using 129B6 cDNA and primers 5′-CACTGCAAACGGGGAAATGG (forward) and 5′-TGAGATGGACTGTCGGATGG (reverse).

For standard curves, a dilution series of cloned *Bax, Bcl-X* and *S16* templates ranging from 10^2^ to 10^9^ copies were used. The quantitative PCR cycling parameters were: 1 cycle of 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Data collection was taken at the 60°C annealing/extension phase. In order to ensure the presence of a single product, a dissociation curve was performed after each run and products were visualized on ethidium bromide-stained agarose gels. Data were collected from threshold values using the automatic function of the 7300 System Sequence Detection Software program. The primers used to quantify *Bax* cDNA yielded a 220 bp fragment that spanned intron 3: 5′-TTCATCCAGGATCGAGCAGG (forward) and 5′-CATCAGCAAACATGTCAGC (reverse). The primers used to quantify *BclX* cDNA yielded a 275 bp fragment: 5′-GCATCGTGGCCTTTTTCTCC (forward) and 5′-CGACTGAAGAGTGAGCCCAG (reverse). All cDNA levels were normalized to murine *S16* ribosomal protein cDNA, which was quantified using the same primers that were used to clone *S16* above. All primers crossed at least one intron/exon boundary. All PCR products generated with these primers were also sequenced to verify identity.

Transfections
-------------

NIH 3T3 cells were plated into 60 cm plates at a density of 1×10^5^ cells/plate. RGC-5 cells and primary fibroblasts were plated into six-well plates with a density of 3×10^4^ cells/well. All cells were transfected 24 h after initial plating. Transfections were performed using the Tfx-50 transfection reagent (Promega) with a 2:1 transfection reagent/DNA ratio for primary fibroblasts and RGC-5 cells and a 3:1 ratio for NIH 3T3 cells. Plasmid DNAs used for transfection were 2 μg of either DBA/2J--Luc or 129B6--Luc along with 1 μg of pSV-βgal to control for transfection efficiency. Empty pGL3-Basic was used as a negative control in all experiments and pGL3-Control was used as a positive control. For transfections into p53^−/−^ fibroblasts, Luc reporter plasmids were co-transfected with pSV-βgal and 1 μg of either pGL3-Basic or pC53-SN~3~ plasmids. For primary fibroblasts and RGC-5 cells, the transfection medium was replaced after 5 h with complete medium in order to increase viability. In NIH 3T3 cells, however, complete medium was added directly to the transfection medium after 1 h. Reporter gene activity was typically measured 48 h after transfection, except where noted. Luc activity was measured with Luc assay reagent (Promega) using a Turner TD-20e Luminometer (Sunnyvale, CA) and β-gal activity was measured using β-gal assay reagent (Promega) and reading the absorbance at 420 nm in a spectrophotometer.

EMSA (electrophoretic mobility-shift assay)
-------------------------------------------

EMSA and unlabelled competition EMSA were performed using double-stranded 30 bp oligonucleotides encompassing the polymorphic site from −499 to −528 of the 129B6 or DBA/2J *Bax* promoters. When making probes for EMSA, complementary strands of the 30 bp 129B6 or DBA/2J *Bax* promoter regions (400 pmol) were annealed in 100 μl of annealing buffer (10 mM Tris/HCl, pH 7.5, and 20 mM NaCl). The double-stranded oligonucleotides (16 pmol) were end-labelled using \[γ-^32^P\]ATP (6000 Ci/mmol; Amersham) and T4 Polynucleotide Kinase (Promega). Free radioactivity was removed using illustra^TM^ Microspin G-25 Columns (Amersham). Probes were counted in a Packard TRI CARB 2100TR liquid scintillation analyser (Canberra, Meriden, CT, U.S.A.). NIH 3T3 nuclear extract was purchased from Santa Cruz Biotechnology. Whole retinal nuclear protein isolations were performed as described previously ([@B3]). Nuclear extracts (5 μg) were incubated for 10 min at room temperature (22°C) with binding buffer \[5 mM MgCl~2~, 2.5 mM EDTA, 2.5 mM DTT (dithiothreitol), 250 mM NaCl and 50 mM Tris/HCl, pH 7.5\] and 3 μg of dI-dC (Amersham) per lane. A ^32^P-labelled probe (600 000 c.p.m./lane; ∼0.12 pmol) was then added in the presence of excess (6.25- to 150-fold where noted) or absence of unlabelled competitor oligonucleotides and incubated for 20 min at room temperature. The reactions were run on a 5% polyacrylamide gel in 0.5× Tris-borate EDTA buffer at 250 V for 2 h. Gels were dried and exposed to a PhosphorImager screen (Molecular Dynamics), scanned on a Storm 860 scanner (Amersham), and band density was quantified using ImageQuant software v5.2 (Amersham).

Immunoblotting
--------------

Immunoblots were performed as described previously ([@B4]) with a few modifications. Whole brain lysates (60 μg/lane) from 129B6 and DBA/2J mice were used in the assay. Protein concentration was quantified using a BCA (bicinchoninic acid) protein assay (Pierce). The following antibodies were utilized to detect specific antigens. Polyclonal antibodies developed in rabbit, anti-BAX antibody (B3428) and anti-actin antibody (A2066) were purchased from Sigma and used at 1:2000 and 1:100 dilutions respectively. The secondary antibody was alkaline-phosphatase-conjugated and the blot was visualized utilizing ECF Substrate (Amersham Biosciences). Blots were scanned on a Storm 860 scanner (Amersham), and band density quantified using ImageQuant software v5.2 (Amersham).

Quantitative analysis of BCL-X and BAX protein levels were examined using blot strips. Equal protein amounts of retinal lysates were each run in single oversized lanes on 12% polyacrylamide gels. After transblotting to Immobilon-P membranes, each lane was divided into three equal-sized strips, and each strip was individually probed with polyclonal antibodies for actin, BAX or BCL-X (sc-634, Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.; 1:1000 dilution). After probing with secondary antibody, the blots were developed using colorimetric staining for alkaline phosphatase activity in Nitro-Blue Tetrazolium and BCIP (5-bromo-4-chloroindol-3-yl phosphate). Staining for BCL-X and BAX was allowed to continue until one of the comparative strips had reached saturation.

*In silico* analysis
--------------------

The 10 bp core sequence from the 129B6 *Bax* promoter, AGGTTTGCCT, was entered as a search term in a number of different transcription factor databases all available online: JASPAR (<http://mordor.cgb.ki.se/cgi-bin/jaspar2005/jaspar_db.pl>), TESS (<http://www.cbil.upenn.edu/cgi-bin/tess/tess>), TFSearch (<http://www.cbrc.jp/research/db/TFSEARCH.html>) and MatInspector from Genomatix (<http://www.genomatix.de>). For the initial screen of transcription factors putatively binding to the core sequence, any sequence not possessing at least 60% homology with the core was eliminated. Other parameters taken into account were transcription-factor-binding sequences that matched a portion of the core sequence, including the polymorphic site, with high sequence similarity and in the correct succession of base pairs. The likelihood of that particular transcription factor being expressed in mouse neurons was also considered.

Statistical analyses
--------------------

For data presented as means±S.E.M., assessment for significant differences between groups was performed by Student's *t* test. The data from quantified EMSA gels were plotted, best-fit curves generated, and IC~50~ values were calculated using Kaleidagraph 4 software (Synergy Software).

RESULTS
=======

Genetically distinct mice, heterozygous for mutant*Bax*, display susceptible or resistant RGC death phenotypes in response to ONC
---------------------------------------------------------------------------------------------------------------------------------

ONC in mice causes the selective death of RGCs that generally progresses to maximal cell loss by 3 weeks after surgery in wild-type animals ([@B26]; [@B28]). We initially investigated the effects of *Bax* gene dosage on RGC survival in 129B6 mice and DBA/2J mice at an intermediate term period (2 weeks) after ONC ([Figure 1A](#F1){ref-type="fig"}). DBA/2J*^Bax^*^+/+^ mice had 66% cells remaining, which represents a loss of 34.0±2.45% of the cells in the ganglion cell layer relative to the control retina (*P*\<0.001). Likewise, 129B6*^Bax^*^+/+^ mice had 62.3% of their cells remaining, or a loss of 37.7±5.3% of the cells in the ganglion cell layer relative to control retinas (*P*\<0.005). DBA/2J*^Bax^*^−/−^ and 129B6*^Bax^*^−/−^ were completely resistant to the damaging effects of ONC (*P*\>0.25 for DBA/2J*^Bax^*^−/−^, *P*\>0.10 for 129B6*^Bax^*^−/−^ relative to control). Importantly, animals heterozygous for *Bax* exhibited distinctly different phenotypes. 129B6*^Bax^*^+/−^ mice displayed significant cell death after ONC (*P*\<0.005), similar to wild-type animals. DBA/2J*^Bax^*^+/−^ displayed no significant cell death (*P*\>0.25), similar to *Bax*^−/−^ animals. The results observed for 129B6*^Bax^*^+/−^ and DBA/2J*^Bax^*^+/−^ were consistent with previously published reports of cell death after acute nerve trauma in these two lines ([@B9]; [@B29]). In order to examine if there was long-term protection of RGCs in *Bax*^+/−^ mice, experiments examining RGC loss in resistant DBA/2J*^Bax^*^+/−^ mice at both 3 and 8 weeks post-ONC were performed ([Figures 1B--1G](#F1){ref-type="fig"}). Mice at 3 weeks after ONC still showed dramatic preservation of cells in the ganglion cell layer (∼90% of control retinas), but a significant loss of cells by 8 weeks (72.3±3.4% cells remaining, *P* = 2.85×10^−6^). This loss of cells was still well below that for *Bax*^+/+^ mice at 3 weeks, which exhibited only 45.8±1.7% of the cells present in control retinas, and probably accounts for complete elimination of the RGC population in this retinal layer. Conversely, *Bax*^−/−^ RGC somas survive up to 18 months after optic nerve damage, exhibiting more than 92% cells remaining at that point.

![Retinal ganglion cell death after ONC in 129B6 and DBA/2J mice\
(**A**) Histograms of the mean±S.E.M. cells remaining in the retinal ganglion cell layer 2 weeks after ONC in DBA/2J and 129B6 mice. Both 129B6*^Bax^*^−/−^ and DBA/2J*^Bax^*^−/−^ mice showed no significant loss of cells relative to control eyes (*P*\>0.10 and *P*\>0.25 respectively), whereas wild-type mice showed significant loss (*P*\<0.005). DBA/2J*^Bax^*^+/−^ mice displayed a knockout phenotype, showing no significant loss (\*\**P*\>0.25), whereas 129B6*^Bax^*^+/−^ exhibited significant cell loss similar to wild-type animals (\**P*\<0.001). After a prolonged period after ONC, however, resistant heterozygous mice also exhibit cell loss. (**B**--**F**) Nissl-stained cells in the ganglion cell layer of whole mounted mouse retinas. A region of approx. 10^4^ μm^2^ of the superior mid-peripheral retina of each eye is shown. (**B**) Control retina from a *Bax*^+/−^ mouse. (**C**) Retina from a *Bax*^+/−^ mouse, 3 weeks after ONC. Minimal cell loss is observed, compared with control. (**D**) Retina from a *Bax*^+/−^ mouse, 8 weeks after ONC. These mice exhibit moderate cell loss and partial atrophy, typified by cell soma shrinkage of the remaining ganglion cell population, which is common in *Bax*-deficient neurons after damage ([@B27]; [@B50]). (**E**) Retina from a *Bax*^+/+^ mouse, 3 weeks after ONC. These mice typically exhibit a maximum loss of ganglion cells by this stage. A cell undergoing apoptosis is indicated by the arrow. (**F**) Retina from a *Bax*^−/−^ mouse, 18 months after ONC. Even at this extended time after a lesion to the nerve, there is minimal loss of cells in the ganglion cell layer. Note that *Bax*^−/−^ animals have a higher density of ganglion cells than either wild-type or heterozygous mice because of the lack of *Bax*-dependent programmed cell death, which normally prunes approx. 50% of the ganglion cell population during the first few weeks of life ([@B38]; [@B43]). Scale bar, 15 μm. (**G**) Quantitative analysis of the change in cell numbers in experimental retinas 3 weeks, 8 weeks and 18 months after ONC. Results are presented as a percentage of cells (means±S.E.M.) counted in the control fellow eyes of all mice examined. *Bax* heterozygous animals were on the DBA/2J background, whereas *Bax*^−/−^ mice were on the 129B6 background for this experiment. A total of five to seven mice were analysed for each condition, except for *Bax*^−/−^ mice at 18 months, in which two mice were examined. (\**P* = 2.85×10^−6^ and \*\**P* = 7.78×10^−18^, both compared with control fellow eyes of mice used in each group).](an002e032f01){#F1}

DBA/2J*^Bax^*^+/−^ and 129B6*^Bax^*^+/−^ mice express different neuronal levels of *Bax*
----------------------------------------------------------------------------------------

We then examined if the variation in susceptibilities between heterozygous DBA/2J and 129B6 mice was either due to a difference in BAX protein function caused by an amino acid substitution or the level of expression. Sequence analysis of cDNAs isolated from the DBA/2J and 129B6 strains yielded no difference in predicted amino acid structure (data not shown). This ruled out the possibility that a difference in BAX protein function as a consequence of an amino acid sequence difference was the underlying cause of the phenotype. We then investigated whether there was a difference in neuronal *Bax* expression. Quantitative PCR was used to quantify *Bax* mRNA levels in the retinas of 129B6 and DBA/2J mice ([Figure 2A](#F2){ref-type="fig"}). As the number of RGCs that populate the ganglion cell layer in DBA/2J and 129B6 retinas are comparable, and *Bax* mRNA has been shown to be principally localized to the RGC layer of adult rats ([@B49]), we used whole retinal cDNA for analysis. In each strain, neuronal *Bax* mRNA levels were reduced by approx. 50% in heterozygous mice relative to wild-type mice. *Bax*^−/−^ mice of either strain expressed no detectable *Bax* mRNA. Retinas from 129B6 mice contained twice the level of *Bax* mRNA compared with DBA/2J mice, such that 129B6*^Bax^*^+/−^ and DBA/2J*^Bax^*^+/+^ animals had similar levels of *Bax* transcripts (*P* = 0.46) ([Figure 2A](#F2){ref-type="fig"}). Consistent with the mRNA levels, 129B6*^Bax^*^+/+^ neurons expressed 1.2- to 1.8-fold (range for three separate experiments) the BAX protein level as DBA/2J*^Bax^*^+/+^ neurons ([Figure 2B](#F2){ref-type="fig"}). Similarly, BAX protein measurements indicated that 129B6*^Bax^*^+/−^ neurons had between 1.4- and 2.0-fold (range for three separate experiments) the amount of BAX protein as DBA/2J*^Bax^*^+/−^ neurons. *Bax*^−/−^ mice expressed no detectable BAX protein ([Figure 2B](#F2){ref-type="fig"}). These observations correlated the higher susceptibility to ONC observed in 129B6^+/−^ mice ([Figure 1A](#F1){ref-type="fig"}) with latent levels of *Bax* mRNA and protein.

![DBA/2J and 129B6 mice differentially express *Bax*\
(**A**) Quantitative PCR analysis of latent *Bax* transcript levels (means±SEM) in 129B6 and DBA/2J mice. Values shown are the number of *Bax* mRNA molecules \[per 2.5 pg of poly(A) RNA input\] normalized to the number of *S16* molecules in each sample. Reducing *Bax* gene dosage to one gene caused a 50% reduction of *Bax* transcripts (for 129B6, *P* = 0.004, for DBA/2J, *P* = 0.002, control retinas of *Bax*^+/−^ mice compared with control retinas of *Bax*^+/+^ mice) and no transcripts were detected in knock-out mice. Similarly, 129B6 mice had approximately twice the amount of *Bax* mRNA in the retina (\*129B6*^Bax^*^+/+^ compared with DBA/2J*^Bax^*^+/+^ mice, *P* = 0.008; \*\*129B6*^Bax^*^+/−^ compared with DBA/2J*^Bax^*^+/−^ mice, *P* = 0.002). (**B**) Representative immunoblot showing relative Bax protein levels in DBA/2J and 129B6 neurons. Bax protein levels were 1.2- to 1.8-fold higher in 129B6*^Bax+/+^* mice compared with DBA/2J*^Bax^*^+/+^ mice (when normalized to actin in each lane). Similarly, 129B6*^Bax^*^+/−^ mice expressed 1.4- to 2.0-fold as much Bax as DBA/2J*^Bax^*^+/−^ mice. No Bax protein was detected in *Bax*^−/−^ mice. (**C**) Histogram of *BclX* transcript levels in the retinas of *Bax* heterozygous mice from each strain. Unlike *Bax* mRNA, no difference in *BclX* mRNA was detected between strains (*P* = 0.26), or between wild-type and knockout mice (data not shown). (**D**) Blot strips taken from the same lanes of retina homogenates of wild-type DBA/2J or 129B6 mice. To accurately assess the relative levels of BAX and BCL-X, the strips were developed equally, until BCL-X staining began to saturate the colorimetric reaction. BCL-X shows up as two prominent bands, probably reflecting modified and deamidated polypeptides ([@B19]). BAX levels, under these conditions, are just detectable. Chemiluminescence detection of BAX staining clearly shows, however, that this antibody specifically interacted with BAX protein in similar samples (see **B**). Actin was also evaluated as a loading control. (**E**) Histogram showing changes in *Bax* transcript abundance (means±S.E.M.), 4 days after ONC. Retinal transcript levels were examined at 4 days after injury when others have reported moderate increases in *Bax* mRNA after optic nerve axotomy ([@B39]). ONC caused a 42.0±13.2% decrease in *Bax* mRNA in DBA/2J mice relative to control eyes (\**P* = 0.003) and a 79.0±3.8% decrease in 129B6 mice relative to control eyes (\*\**P* = 4.6×10^−5^). The control retinas of 129B6*^Bax^*^+/+^ mice contained 2.2-fold the amount of *Bax* mRNA compared with control DBA/2J*^Bax^*^+/+^ retinas (*P* = 2.0×10^−4^). Thus *Bax* expression was not differentially increased between strains, and instead showed a relative decrease after injury.](an002e032f02){#F2}

Even though the lower levels of latent *Bax* mRNA and protein in DBA/2J mice were associated with resistance to ONC in heterozygous animals, we investigated if other factors may also be affecting this phenotype. Since cell death is influenced in a stoichiometric fashion by the levels of anti-apoptotic and BH3-only members of the *Bcl2* gene family, we also examined mouse retinas for the expression of antagonistic anti-apoptotic genes. Previously, we had described *BclX* as the dominant anti-apoptotic *Bcl2* family member expressed in the retina ([@B25]). No significant difference in *BclX* transcript level was observed between *Bax*^+/+^ and*Bax*^−/−^ of each strain (data not shown). Importantly, there was no significant difference in *BclX* transcript levels between 129B6*^Bax^*^+/−^ and DBA/2J*^Bax^*^+/−^ (*P* = 0.26, [Figure 2C](#F2){ref-type="fig"}). Furthermore, in direct quantitative analyses of the same tissues, *BclX* transcripts were also 5--10-fold more abundant than *Bax* transcripts (compare [Figure 2A](#F2){ref-type="fig"} with [Figure 2C](#F2){ref-type="fig"}). To verify that there was also in increased level of BCL-X protein, predicted by the mRNA levels, we examined relative BCL-X and BAX protein concentrations in retina homogenates of wild-type 129B6 and DBA/2J mice. Strips cut from the same lanes of sample run on SDS/12% polyacrylamide gels were individually probed with antibodies against BCL-X, BAX and actin (to control for loading differences). Strips developed for equal periods of time for BCL-X and BAX showed a strong reaction for BCL-X, but BAX levels were only just detectable ([Figure 2D](#F2){ref-type="fig"}). Thus, BCL-X protein levels appeared to be in excess over BAX in both samples, consistent with the quantitative PCR data.

Some studies have suggested that *Bax* expression is increased in RGCs after optic nerve damage ([@B17]; [@B39]). Although this increase in expression has been refuted by others ([@B35]), we nevertheless explored the possibility that *Bax* was differentially up-regulated after crush in the two mouse lines. Quantitative analysis of *Bax* transcript levels in mouse retinas 4 days after ONC indicated that *Bax* mRNA levels were not induced in the retina ([Figure 2E](#F2){ref-type="fig"}). Instead, each strain exhibited a significant decrease in transcript abundance (DBA/2J Control compared with 129B6 Control, *P* = 2×10^−4^; DBA/2J Control compared with DBA/2J Crush, *P* = 0.003; 129B6 Control compared with 129B6 Crush, *P* = 1×10^−4^).

A single-nucleotide polymorphism in the*Bax* gene promoter is associated with a decrease in transcriptional activity
--------------------------------------------------------------------------------------------------------------------

To investigate the mechanism underlying differential *Bax* expression, we examined the promoter regions for differences in *cis*-element sequences. For this, we cloned 1370 bp of the *Bax* promoter regions directly upstream of the translation start site from the DBA/2J and 129B6 mouse lines and compared them by sequence analysis. Both promoters were identical with the exception of a single T (in 129B6) to a C (in DBA/2J) polymorphism at position −515 upstream from the start of translation ([Figure 3](#F3){ref-type="fig"}). This polymorphism was verified in six independent mice of each strain. Analysis of potential binding sites in this region showed that the polymorphism existed within a potential p53 half-site in the DBA/2J line. We tested the ability of this polymorphism to affect transcription *in vitro* by fusing 1370 bp of the promoter region of each strain to a Luc reporter gene. Transient transfection experiments into both non-neuronal NIH 3T3 cells and RGC-derived RGC-5 cells showed that 129B6--Luc consistently exhibited 1.5-fold the expression level of DBA/2J--Luc in immortalized cells (*P* = 3×10^−4^ and *P* = 1.71×10^−12^ respectively, [Figure 4](#F4){ref-type="fig"}). Transient transfections into primary fibroblasts isolated from DBA/2J and FVB mice showed 129B6--Luc expression to be 2.5- and 2.3-fold higher than DBA/2J--Luc expression (*P* = 0.002 and *P* = 2.82×10^−6^ respectively), which was similar to the difference in *Bax* transcript levels between 129B6 and DBA/2J mice. Thus the higher expression observed *in vitro* from 129B6--Luc suggested that this polymorphism was, at least in part, responsible for the difference in*Bax* expression observed *in vivo*.

![Diagram of 1370 bp of the murine *Bax* promoter region\
The *Bax* promoter region from the DBA/2J and 129B6 mouse lines was isolated, sequenced, and compared. The nucleotide directly upstream of the translation start site is indicated as −1 in the first exon and numbering of the murine *Bax* promoter is relative to this position. Depicted are the sequences of 30 bp of the 129B6 and DBA/2J promoter regions at positions −499 to −528. A single nucleotide polymorphism (outlined with a dashed box) was found at position −515. The core p53 half-site recognition sequence is Pu Pu Pu C A/T A/T G Py Py Py (where Pu, purine; Py, pyramidine) ([@B11]). The DBA/2J promoter has a perfect consensus sequence (underlined). Other putative transcription factor binding sites are also shown as previously described ([@B16]).](an002e032f03){#F3}

![Expression from 129B6--Luc is higher than DBA/2J--Luc in both immortalized non-neuronal and neuronal cell lines and primary fibroblasts\
DBA/2J--Luc or 129B6--Luc were transiently co-transfected with pSV-βgal into NIH 3T3 murine fibroblasts, RGC-5 cells, or primary fibroblasts derived from either DBA/2J mice or FVB mice. The histogram represents the mean Luc levels (in RLU, relative light units) normalized to βgal activity (±S.E.M.) of three to five experiments, with three to six replicates for each condition in each experiment. 129B6--Luc exhibited 1.5-fold the expression of DBA/2J--Luc in NIH 3T3 cells and RGC-5 cells (\**P* = 3×10^−4^ and \*\**P* = 1.71×10^−12^ respectively). In transient transfections of primary fibroblasts from DBA/2J and FVB mice, 129B6--Luc exhibited 2.5- and 2.3-fold the expression, respectively, of DBA/2J--Luc (\*\*\**P* = 0.002 and \*\*\*\**P* = 2.82×10^−6^ respectively). These results are consistent with higher levels of *Bax* mRNA in neurons of 129B6 mice. Cells from 129B6 mice were excluded from this analysis because they exhibited poor growth kinetics in primary cultures.](an002e032f04){#F4}

The difference in the level of expression between DBA/2J--Luc and 129B6--Luc is not regulated by p53
----------------------------------------------------------------------------------------------------

We first determined if nuclear proteins interacted with the polymorphic site. EMSAs were performed using radiolabelled 129B6 or DBA/2J probes spanning 30 bp, including the polymorphic site (see [Figure 3](#F3){ref-type="fig"}), and nuclear extracts isolated from NIH 3T3 cells or retinal tissue. Retinal nuclear extracts were derived from either 129B6 or DBA/2J mice, both yielding the same result. Only data from the 129B6 extract is shown. NIH 3T3 and retinal nuclear extract produced two predominant shifted complexes, Complex 1 and Complex 2, compared with lanes with no nuclear extract ([Figure 5](#F5){ref-type="fig"}). Although Complex 2 consisted of multiple bands, these bands behaved similarly in competition assays (data not shown) and were treated as a single complex during analyses. The polymorphism in the DBA/2J promoter was contained within a consensus p53 half-site. Two of these p53 half-sites, 0--13 bp apart, are typically required for effective p53 binding ([@B11]). Others have shown, however, that p53 half-sites can mediate expression, which involved p53 binding, by remotely interacting with other *cis*-elements ([@B36]). The change of a T(129B6) to a C(DBA/2J) at the −515 position would putatively increase p53 interactions with the DBA/2J half-site.

![Both NIH 3T3 and retinal nuclear extracts produced two shifted complexes in EMSA\
A representative PhosphorImager-generated autoradiograph of an EMSA performed with ^32^P-labelled 129B6 or DBA/2J double-stranded probe (−499 to −528 sequence in [Figure 3](#F3){ref-type="fig"}) is shown. No shifted complexes were formed in the absence of nuclear extract. Nuclear extracts from both fibroblasts and 129B6 retinal tissue (5 μg of total protein each) formed two shifted complexes denoted as Complex 1 and Complex 2. Three separate extracts, from each tissue source, are shown.](an002e032f05){#F5}

We initially tested the hypothesis that binding of p53, principally to the DBA/2J polymorphism, may be acting to repress transcription. To examine p53 involvement, unlabelled competition EMSA was first performed with a 50-fold molar excess of a concatemer of four p53 half-sites ([Figures 6A and 6B](#F6){ref-type="fig"}). The unlabelled p53 half-site concatemer competed specifically with Complex 1 (*P* = 4.23×10^−10^). This result was consistent with possible involvement of p53, but importantly indicated that DNA--protein interactions of Complex 1 included the polymorphic region. To test the effects of p53 directly, we transiently transfected DBA/2J--Luc and 129B6--Luc into primary fibroblasts isolated from p53^−/−^ FVB mice, to determine if the differential expression observed between the two promoters was lost in the absence of p53. In p53^−/−^ fibroblasts, 129B6--Luc expression was approx. 1.5-fold higher than DBA/2J--Luc (*P* = 0.03), and in p53^+/+^ cells 129B6--Luc expression was twice as high as DBA/2J--Luc expression (*P* = 0.003, see FVB cells in [Figure 4](#F4){ref-type="fig"}). As a control, we also co-transfected the cells with a plasmid expressing exogenous p53 (pC53-SN~3~). The addition of exogenous p53 did not significantly transactivate or repress either DBA/2J--Luc (*P* = 0.16, compared with no p53) or 129B6--Luc (*P* = 0.30) expression ([Figure 6C](#F6){ref-type="fig"}). Conversely, a reporter construct with 13 p53 consensus sites (pG13--Luc) exhibited 8-fold more Luc expression after the addition of exogenous p53 compared with cells without p53 (*P* = 0.0001, [Figure 6C](#F6){ref-type="fig"}). Importantly, differential expression between DBA/2J--Luc and 129B6--Luc was not affected by the presence or absence of p53. In order to confirm these data, we examined if the EMSA-binding pattern was altered in nuclear extracts isolated from p53^−/−^ cells. Extracts from both p53^+/+^ and p53^−/−^ fibroblasts (with an otherwise identical genetic background) yielded identical EMSA banding patterns, including Complex 1 (data not shown). Lastly, super-shifting either complex with a p53 antibody was unsuccessful (data not shown).

![p53 does not regulate differential expression of the *Bax* promoter\
(**A**) PhosphorImager-generated autoradiograph of a competition EMSA using the 129B6 probe and 129B6 retina extract. In order to test possible p53 involvement, unlabelled competition EMSA was performed with a 50-fold molar excess of a concatemer of four p53 half-sites and compared with the DBA/2J and 129B6 unlabelled competitors at a 50-fold molar excess (consisting of the 30 bp highlighted in [Figure 3](#F3){ref-type="fig"}). The unlabelled p53 half-site concatemer competed specifically with Complex 1, whereas DBA/2J and 129B6 oligos competed with both Complexes. NC, lane containing no competitor. (**B**) Histogram showing quantification of percentage inhibition of Complex 1 and 2 formation compared with NC (means±SEM). The amount of complexed probe in the presence of no competitor DNA was assigned a value of 100% and subsequent competitor lanes are expressed as a percentage of this. The p53 consensus sequence, DBA/2J sequence and 129B6 sequence all significantly competed Complex 1 (\**P*\<0.01;*P* = 4.23×10^−10^, *P* = 5.17×10^−8^ and *P* = 2.13×10^−10^ respectively compared with NC. The p53 consensus sequence did not significantly compete Complex 2 (*P* = 0.45), whereas the DBA/2J and 129B6 sequences did (\*\**P*\<0.01; *P* = 6.29×10^−5^ and *P* = 1.10×10^−5^ respectively). (**C**) Histogram of Luc activity in transient transfections of p53^−/−^ fibroblasts (FVB mice). *Bax*--Luc constructs were co-transfected with pSV-βgal and either pGL-Basic (-p53) or pC53-SN~3~ (+p53). The 129B6--Luc construct had higher expression than the DBA/2J--Luc construct with or without addition of exogenous p53 (*P* = 0.03 and *P* = 0.006, respectively). Although there was a trend toward an increase in expression from DBA/2J--Luc and 129B6--Luc when co-transfected with human p53, compared with p53^−/−^ cells transfected with a non-expressing control vector, the increase was not statistically significant (DBA/2J, *P* = 0.16; 129B6, *P* = 0.30). These results are consistent with other reports showing that p53 does not transactivate the murine *Bax* promoter ([@B16]; [@B48]; [@B51]). The p53-responsive vector, pG~13~--Luc, exhibited a significant increase in expression with co-transfection of human p53 (*P* = 0.0001), indicating that the exogenous p53 was biologically active in these cells.](an002e032f06){#F6}

The single nucleotide polymorphism affects the binding affinity of nuclear proteins
-----------------------------------------------------------------------------------

Because p53 was ruled out as a transcription factor that affected the difference in expression, we determined if the polymorphism affected the binding affinity of other nuclear proteins. Competition EMSA was performed to determine relative binding affinities for the polymorphic site. Complexes formed on radiolabelled DBA/2J or 129B6 probes were competed with increasing fold molar excess of either unlabelled DBA/2J DNA or unlabelled 129B6 DNA. The inhibition constants at half the labelled complex formation (IC~50~) were calculated using Kaleidagraph software from the values of band density in each lane~.~ The values were plotted and a best-fit curve generated ([Figure 7A](#F7){ref-type="fig"}). For Complex 1, the IC~50~ value for the DBA/2J radiolabelled probe competed with unlabelled DBA/2J DNA was 5.07±0.39 (fold molar excess) and with unlabelled 129B6 DNA was 1.04±0.06. The IC~50~ for the 129B6 radiolabelled probe compared with unlabelled DBA/2J DNA was 8.62±0.35 and compared with unlabelled 129B6 DNA was 2.47±0.16 ([Figure 7B](#F7){ref-type="fig"}). Thus, 4--5-fold more unlabelled DBA/2J DNA, relative to unlabelled 129B6 DNA, was required to inhibit half of the radiolabelled complex from each probe. These results suggested that the protein(s) forming Complex 1 had a higher affinity for the 129B6 site. For Complex 2, the IC~50~ value of the DBA/2J radiolabelled probe co-competed with DBA/2J unlabelled DNA was 180.53±8.95 and with 129B6 unlabelled DNA was 132.63±10.91 ([Figure 7B](#F7){ref-type="fig"}). The IC~50~ for Complex 2 of the 129B6 radiolabelled probe compared with the unlabelled DBA/2J DNA was 198.14±19.45 and compared with unlabelled 129B6 DNA was 128.57±10.85 ([Figure 7B](#F7){ref-type="fig"}). The IC~50~ ratios of Complex 2 indicated that the protein(s) forming this complex exhibited similar binding affinities for both the DBA/2J and 129B6 DNAs. These data indicated Complex 1 was formed via DNA--protein interactions with the polymorphic site, whereas Complex 2 was probably formed with DNA--protein interactions elsewhere on the 30 bp sequence. To confirm this, we also performed unlabelled competition EMSA with separate regions of the 30 bp sequence ([Figure 8](#F8){ref-type="fig"}). Complex 2 formation was inhibited most successfully with a unlabelled 10 bp DNA fragment upstream of the polymorphic site, suggesting that this region was principally involved in Complex 2 formation.

![Nuclear proteins forming Complex 1 bind with higher affinity to the 129B6 polymorphic site\
(**A**) Representative PhosphorImager-generated autoradiographs of unlabelled co-competition experiments. Top two panels: 600000 c.p.m./lane (0.12 pmol) of radiolabelled DBA/2J probe (left panel) or radiolabelled 129B6 probe (right panel) were reacted with either no or 5 μg of 129B6 retinal nuclear extract. Complexes were also incubated with no competitor DNA (NC) or increasing molar excess of unlabelled DBA/2J competitor DNA. Increasing molar excess caused inhibition of the formation of radiolabelled Complex 1 and Complex 2 compared with lanes with no competitor DNA. Bottom two panels: same probes as the top two panels with increasing amounts of unlabelled 129B6 competitor DNA. (**B**) Graphs plotting fold molar excess of DNA compared with band density of complexed probe obtained from analysing PhosphorImager-generated autoradiographs using ImageQuant v5.2 software. Kaleidograph software was then used to generate graphs and calculate IC~50~ values. The mean (±S.E.M.) complex formed in three separate experiments are shown. The amount of complexed probe in the presence of no competitor DNA was assigned a value of 100% and subsequent competitor lanes are expressed as a percentage of this. As the fold molar excess competitor DNA increases, there is increased inhibition of radiolabelled complex formation. Top panels: radiolabelled DBA/2J probe (left) or radiolabelled 129B6 probe (right) compared with increasing fold molar excess of DBA/2J or 129B6 unlabelled competitor DNA for Complex 1. For Complex 1, the IC~50~ value of DBA/2J radiolabelled probe (left) co-competed with unlabelled DBA/2J DNA was 5.07±0.39 and with unlabelled 129B6 DNA was 1.04±0.06. The IC~50~ for 129B6 radiolabelled probe (right) compared with unlabelled DBA/2J DNA was 8.62±0.35 and compared with unlabelled 129B6 DNA was 2.47±0.16. Approx. 4--5-fold more DBA/2J unlabelled DNA relative to unlabelled 129B6 DNA was required to inhibit half of the radiolabelled complex. These data suggest that the protein(s) forming Complex 1 have a higher affinity for the 129B6 site. Bottom panels: radiolabelled DBA/2J probe (left) or radiolabelled 129B6 probe (right) versus increasing fold molar excess of DBA/2J or 129B6 unlabelled competitor DNA for Complex 2. The IC~50~ value of the DBA/2J radiolabelled probe (left) co-competed with DBA/2J unlabelled DNA was 180.53±8.95 and with 129B6 unlabelled DNA was 132.63±10.91. The IC~50~ for Complex 2 of the 129B6 radiolabelled probe (right) compared with unlabelled DBA/2J DNA was 198.14±19.45 and compared with unlabelled 129B6 DNA was 128.57±10.85. The IC~50~ ratios of Complex 2 indicate that the protein(s) forming this complex exhibit similar binding affinities for both the DBA/2J and 129B6 DNAs.](an002e032f07){#F7}

![Complex 2 is formed by DNA--protein interactions involving nucleotides upstream of the polymorphic site\
(**A**) Shown is the 30 bp sequence delineating unlabelled competitor DNAs for the 129B6 polymorphic region. The polymorphic site is denoted by an asterisk. Fragments a, b and c span the individual regions shown. These fragments were used for competition as concatemers of three copies of each 10 bp region. (**B**) Representative PhosphorImager-generated autoradiograph of unlabelled co-competition experiments with different competitor DNAs reacting with 129B6 retinal extract. The radiolabelled 129B6 full-length probe was incubated in the presence or absence of unlabelled competitor DNAs. Each competitor DNA was used at a 150-fold molar excess of potential binding sites. Competitor a specifically competed Complex 2, while b competed Complex 1, but minimally competed Complex 2. Alternatively, oligo bc efficiently competed Complex 2. These results suggested Complex 2 was formed with interactions upstream of the polymorphic site, but may also involve interactions further downstream of this site.](an002e032f08){#F8}

DISCUSSION
==========

Several neuronal populations require *Bax* for cell death during development. *Bax* deficiency resulted in an increase in neuronal numbers in regions such as the cerebellum, hippocampus and retina ([@B38]; [@B53]). Importantly, *Bax* gene dosage was shown to be critical for susceptibility to RGC death in the DBA/2J mouse glaucoma model and after ONC ([@B29]).

Similarly, we demonstrated that retinal ganglion cell somas of DBA/2J mice heterozygous for the mutant *Bax* allele exhibited resistance to cell death in response to an acute crush lesion of the optic nerve, when assayed at 2 weeks after ONC. Unlike completely *Bax*-deficient cells, which exhibit essentially permanent resistance to optic nerve lesion, *Bax^+/−^* cells, which have short-term resistance to ONC (at 2 weeks), eventually die over a much longer time frame. A distinct cell death phenotype was observed for *Bax^+/−^* mice on the 129B6 background, however, in that these ganglion cells died with similar kinetics to wild-type cells.

The variation in cell death phenotype associated with *Bax* genotype appeared to be related to the relative level of latent *Bax* mRNA and protein in affected cells. Quantitative analysis of *Bax* transcript and protein levels showed that 129B6 neuronal populations (including retina and brain) expressed approximately twice the level of gene product than did equivalent cells of DBA/2J mice. Importantly, 129B6*^Bax+/−^* mice expressed approximately the same amount of *Bax* mRNA and protein as wild-type DBA/2J animals, thus providing one explanation for why animals of both these genotypes exhibited essentially normal levels of ganglion cell death. Taking the level of *Bax* expression in these mice as a starting point, two important observations are made with respect to the level of *Bax* and the ability of these neurons to execute apoptosis. Lowering *Bax* expression levels by half from this point, as was observed in DBA/2J*^Bax+/−^* mice, was a sufficient reduction in BAX to make ganglion cells substantially resistant to ONC, at least in the short term. Conversely, doubling *Bax* expression levels from the same point, as was observed in 129B6*^Bax+/+^* mice, had no increased effect on the rate of cell death. This latter observation is consistent with earlier reports that transgenic mice overexpressing wild-type *Bax* showed no increase in normal developmental programmed cell death ([@B5]), and underscores a hypothetical concept that cells require a set threshold of *Bax* expression, which allows them to completely commit to the apoptotic program once it has been activated. This threshold may also be distinct from the levels of other members of the *Bcl2* gene family. Both lines of mice, regardless of *Bax* genotype, expressed equivalent levels of *BclX* mRNA and protein, which, at the mRNA level, was also in approx. 5--10-fold molar excess. Similarly, preliminary experiments to quantify *Bim* transcripts, which encode a principal BH3-only protein involved in ganglion cell death ([@B39]; [@B34]) also showed no difference between strains (data not shown). Thus the correlation between cell death and *Bax* genotype appears to be mediated primarily by the level of *Bax* expression and not in conjunction with altered levels of other members of the *Bcl2* gene family.

A caveat to the conclusion that lower *Bax* expression levels influence retinal ganglion cell in DBA/2J mice is that there are probably multiple interacting genes that influence the cell death response. These genes could also vary between different genetic backgrounds. For example, previously we reported that DBA/2J mice were more resistant to ONC than BALB/cByJ mice ([@B28]). The difference in phenotype between the strains accounted for approx. 12% of the variance found in the loss of RGCs among mice after this procedure. Examination of the levels of *Bax* expression between strains showed that *Bax* was not the affecting allele, which was later attributed to a quantitative trait locus that mapped to chromosome 5 ([@B10]). Interestingly, wild-type C57BL/6J and 129×1/SvJ, which both contribute to the genetic make-up of129B6 mice, exhibited a cell death phenotype statistically similar to DBA/2J mice. This suggests that influences attributable to different genetic background are not dramatically influencing the relationship between *Bax* expression and cell death we observed in the present study.

Experiments described in the present study establish a link between a single nucleotide polymorphism in the *Bax* promoter with the quantitative difference in *Bax* expression observed between the DBA/2J and 129B6 mouse lines. In transient transfection experiments, the 129B6 polymorphism roughly doubled the transcriptional activity of a Luc reporter gene. It is likely, however, that this *cis*-element is not the only factor affecting *Bax* gene expression quantitatively. Recently, for example, [@B54] described a quantitative and hereditary difference in amacrine cell number in the retinas of C57BL/6J and A/J mice. This quantitative trait was mapped to a locus on chromosome 7, near *Bax*, and was associated with a higher level of *Bax* transcripts in A/J mice. Surprisingly, A/J mice carry the −515(C) polymorphism, similar to DBA/2J mice, whereas C57BL/6J mice carry the −515(T) polymorphism, which is the opposite association of what we would predict from our data presented here. Although no *in vitro* transcription studies were conducted by this group, they hypothesized that differential transcription of the *Bax* allele may be due to enhanced p53 binding to the A/J allele. Since our studies have excluded p53 binding to this region, we predict that differences in genetic background can influence *Bax* transcription both at the level of the *cis*-element polymorphism and the transcriptional machinery interacting with it. Overall, our studies, combined with those of [@B54], underscore the importance of characterizing the transcription factors interacting with this polymorphic site.

Candidates for transcription factors that may interact with this site were examined. Although the polymorphism in the DBA/2J *Bax* promoter creates a perfect consensus p53 half-site ([@B11]), our experiments clearly exclude p53 binding as a critical factor for the differential regulation of *Bax*. We then investigated if the affinity of other nuclear proteins was affected by the polymorphism. Our data suggested that the polymorphism in the *Bax* promoter was sufficient to cause a difference in binding affinity of nuclear proteins. Specifically, nuclear proteins were found to be binding with higher affinity to the 129B6 polymorphic site. Therefore, we predicted that an activator or an activation complex was interacting more efficiently with the 129B6 promoter, resulting in an increase in transcription. The identities of the binding proteins in this region are currently being investigated. Interestingly, artificial transcription factors have been designed to bind to a p53 half-site contained in the human *BAX* promoter with the intention of selectively up-regulating *BAX* and not other p53 targets ([@B12]). An artificial transcription factor containing five zinc-finger-binding motifs, 5ZFAV, was able to elicit significant transactivation from a 40 bp section of promoter containing the consensus p53 half-site. A caveat to this study, however, was that this portion of the promoter also contained three other imperfect p53 half-sites, which could have affected binding and therefore may not be analogous to the mouse polymorphic region.

Alternatively, a search of several transcription-factor-binding-site databases, using the consensus 10 bp surrounding the 129B6 polymorphism, identified other potential transcription factor-binding sites ([Table 1](#T1){ref-type="table"}). None of the sites was a perfect match. Nevertheless, the putative transcription factors identified were activators of transcription, consistent with our prediction that Complex 1 is a positive regulator of transcription. These potential transcription factors included C/EBP (CCAAT/enhancer-binding protein), FOXI1 (Forkhead box I1), and E2F1. E2F1 may be the most promising candidate because of the role it plays in apoptosis. Mice deficient in E2F1, for example, have excess T-cells owing to defects in thymocyte apoptosis, and E2F1 has been shown to activate the expression of *Apaf-1*. Importantly, increased E2F1 activity also resulted in the release of cytochrome *c* ([@B13]). In microarrays, E2Fs have also been implicated in the up-regulation of members of the *Bcl-2* gene family, including *Bad* and *Bak* ([@B32]).

###### *In silico* analysis of transcription-factor-binding sites with similarity to the polymorphic region

A search of transcription factors that can potentially bind the polymorphic region was conducted using the 10 bp core sequence from the 129B6 *Bax* promoter (AGGTTTGCCT). The databases searched included MatInspector, TESS, TFSEARCH and JASPAR. The sequences for putative transcription-factor-binding sites shown in this Table were chosen based on having the highest sequence similarity. Nucleotides that do not align with the polymorphic site are denoted in lower case, whereas exact matches are in upper case. The letter symbols used for nucleotide sequence are as follows: R = G or A, W = T or A, Y = C or T, S = G or C. EBP-45, enhancer-binding protein 45.

  Binding site similarity to AGGTTTGCCT        Factor                                                Notes
  --------------------------------------- ----------------- ---------------------------------------------------------------------------------------
  \- t GTTTGC - -                          EBP-45 or C/EBP   C/EBP found to bind to site, no evidence EBP-45 expressed in neurons ([@B44]; [@B33])
  RRRcWWGYYY                                     p53         Must have two of these half-sites within 13 bp of each other for p53 binding ([@B11])
  \- t RTTTRY - -                               FOXI1                           Forkhead transcription factor ([@B41]; [@B15])
  \- - - TTTSSCgc                               E2F1               Regulation of cell cycle and apoptosis induction ([@B14]; [@B13]; [@B45])

Although experimentally we have demonstrated that the level of *Bax* expression can profoundly affect cell death, we have only been able to detect this phenotype in mice that have been genetically manipulated to have one functional *Bax* gene. Interestingly, however, a similar phenotype has been described in humans. [@B46] noted that patients with chronic lymphocytic leukaemia had a high BCL2/BAX protein ratio. Further examination revealed that a single G to an A polymorphism 248 bp upstream from the translational start site was present in one copy of the *BAX* gene of 69% of the patients. This promoter polymorphism associated with late-stage disease and resistance to treatment. These investigators then demonstrated that this polymorphism was responsible for a 2.6-fold reduction in *BAX* expression ([@B37]). Although the G(−248)A polymorphism in the human *BAX* promoter lies outside of the polymorphism we have detected in the mouse *Bax* promoter, these observations validate the concept that mutations affecting *BAX* expression can influence cell death in disease. Based on our observations in mice, the same or similar polymorphisms in the human *BAX* gene may also contribute to susceptibility of cells in genetically complex neurodegenerative diseases.
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